Outcomes of intrapleural tissue plasminogen activator (tPA) and deoxyribnuclease (DNase) for IPC-related pleural infection Source: International Congress 2019 – Pleural infection and complicated pneumonia Year: 2019
The biological effect of intrapleural tissue plasminogen (tPA) activator and DNase delivery in pleural infection patients. Source: International Congress 2018 – New therapies for respiratory infections: experimental and translational studies Year: 2018
Comparison of intrapleural use of urokinase and tissue plasminogen activator/DNAse in pleural infection Source: ERJ Open Res, 5 (3) 00084-2019; 10.1183/23120541.00084-2019 Year: 2019
Intrapleural tPA increases pleural fluid output in pleural infection, independent of chest X-ray opacification Source: International Congress 2015 – Pneumonia: determinants of clinical outcomes and potential strategies to improve its management Year: 2015
Endogenous thrombin potential (ETP) in pleural effusions Source: Annual Congress 2011 - Molecular markers: diagnosis and management of malignant pleural effusions Year: 2011
An international survey on the use of intrapleural tissue plasminogen activator/DNase therapy for pleural infection Source: ERJ Open Res, 8 (1) 00590-2021; 10.1183/23120541.00590-2021 Year: 2022
Multidisciplinary approach to connective tissue disease (CTD) related pleural effusions Source: International Congress 2018 – Pleural interventions Year: 2018
Role of pleural irrigation with normal saline versus streptokinase in complicated pleural effusions. Source: International Congress 2019 – Interventional pulmonology: current pleural practice Year: 2019
Respiratory functional status after intrapleural t-PA administration for complicated parapneumonic effusions Source: Annual Congress 2012 - Viral infections and rare respiratory infections Year: 2012
Tumour marker (TM) CA 19-9 in pleural fluid at patients with malignant and paramalignant pleural effusion (PE) Source: Eur Respir J 2001; 18: Suppl. 33, 387s Year: 2001
Half - dose of recombinant tissue-type plasminogen activator in the treatment of acute pulmonary embolism: long term outcomes Source: International Congress 2017 – Prognostic factors and outcomes in pulmonary embolism Year: 2017
Difficult pleural effusion management (e.g., chylothorax, trapped lung and rheumatoid effusions) Source: International Congress 2017 – PG5 Pleural disease management Year: 2017
Intrapleural tissue plasminogen activator (tPA) and deoxyribonuclease (DNAse) for pleural infection in an Asian population: Similar outcomes between 5mg and 10mg regimen Source: International Congress 2018 – Clinical challenges in respiratory infection Year: 2018
Diagnostic approach in a patient with pleural effusion Source: ISSN=1025-448x, ISBN=1-904097-25-1, page=131 Year: 2002
Critical issues in pleural fluid examinations: laboratory parameters, tumour markers and cytological methods Source: ISSN=1025-448x, ISBN=1-904097-25-1, page=110 Year: 2002
Pleural NT-PROBNP and albumin gradient (serum-pleural levels difference) in patients with exudative pleural effusion (PE) and previous diuretic therapy Source: Annual Congress 2009 - Pulmonary embolism and cardiovascular diseases Year: 2009
A review of outcomes of indwelling pleural catheters (IPC) for malignant pleural effusions (MPE) at the Cambridge Pleural unit UK Source: Annual Congress 2013 –Interventional pulmonology and pleural diseases Year: 2013
Variable adoption of intrapleural fibrinolytic therapy for pleural space infections Source: International Congress 2018 – Pleural interventions Year: 2018
Iodopovidone pleurodesis in malignant pleural effusion: Is tube clamping time affected the efficacy & safety? Source: Annual Congress 2013 –Chest wall and pleura Year: 2013
Interleukin-8 activates coagulation and correlates with survival after talc pleurodesis Source: Eur Respir J 2010; 35: 160-166 Year: 2010